1. Home
  2. SPRO vs RMBI Comparison

SPRO vs RMBI Comparison

Compare SPRO & RMBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.28

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Logo Richmond Mutual Bancorporation Inc.

RMBI

Richmond Mutual Bancorporation Inc.

HOLD

Current Price

$14.14

Market Cap

128.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
RMBI
Founded
2013
1887
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
136.7M
128.8M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
SPRO
RMBI
Price
$2.28
$14.14
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
281.7K
23.2K
Earning Date
11-13-2025
01-22-2026
Dividend Yield
N/A
4.24%
EPS Growth
N/A
21.88
EPS
N/A
1.06
Revenue
$40,549,000.00
$44,970,551.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.37
Revenue Growth
N/A
6.42
52 Week Low
$0.51
$11.37
52 Week High
$3.22
$15.24

Technical Indicators

Market Signals
Indicator
SPRO
RMBI
Relative Strength Index (RSI) 45.17 54.86
Support Level $2.26 $13.88
Resistance Level $2.37 $14.28
Average True Range (ATR) 0.07 0.28
MACD -0.00 -0.02
Stochastic Oscillator 12.12 53.27

Price Performance

Historical Comparison
SPRO
RMBI

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About RMBI Richmond Mutual Bancorporation Inc.

Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.

Share on Social Networks: